T +1 212 819 8200
Sheryn George is a litigation associate in White & Case's New York office and a member of the Firm's global Competition Group. Her practice focuses on complex antitrust and intellectual property litigation. She regularly represents clients in the pharmaceutical industry, and works on high-profile, "bet the company" cases on the cutting edge of antitrust and intellectual property.
Sheryn has an extensive pro bono practice, and has represented clients in criminal appeals as well as intellectual property disputes.
Prior to joining White & Case, Sheryn clerked for the Honorable Charles R. Wilson of the United States Court of Appeals for the Eleventh Circuit.
Defends Pfizer in federal class action antitrust litigations with respect to Celebrex, accusing the company of delaying entry of generic competition for Celebrex through alleged fraud on the US patent office and sham patent litigation. In re Celebrex Antitrust Litigation (E.D. Va.).
Defends Pfizer in federal consolidated class action antitrust litigations and a state court action brought by the West Virginia Attorney General with respect to Lipitor, accusing the company of delaying entry of generic competition for Lipitor through alleged fraud on the US patent office and sham patent litigation, a sham FDA citizen petition and a reverse payment settlement agreement. In re Lipitor Antitrust Litig., 46 F. Supp. 3d 523 (D.N.J. 2014); State of West Virginia v. Pfizer, Inc., et al. (Cir. Ct., Mason Cty., W.V.).
Defends Pfizer in federal class action antitrust litigations with respect to Effexor XR, accusing the company of delaying entry of generic competition for Effexor XR through alleged fraud on the US patent office, sham patent litigation and a reverse payment settlement agreement. In re Effexor XR Antitrust Litigation, 2014 WL 4988410 (D.N.J. 2014).
Defended a major global pharmaceutical company against Robinson-Patman Act and RICO claims brought by a putative class of end payors, concerning a brand name pharmaceutical manufacturer's assistance program for reducing privately insured patients' co-pay obligations when filling a prescription.
Represented a major global pharmaceutical company in Hatch-Waxman patent litigation against generic manufacturers.
Recent Antitrust Developments: June, July, and August 2013, September 13, 2013: ABA Section of Antitrust Law, Health Care and Pharmaceuticals Committee